India · Delayed Price · Currency is INR Artemis Medicare Services Statistics
Total Valuation
NSE:ARTEMISMED has a market cap or net worth of INR 51.62 billion. The enterprise value is 53.96 billion.
| Market Cap | 51.62B |
| Enterprise Value | 53.96B |
Important Dates
The last earnings date was Monday, August 3, 2026.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | Jul 10, 2026 |
Share Statistics
NSE:ARTEMISMED has 158.31 million shares outstanding. The number of shares has increased by 0.15% in one year.
| Current Share Class | 158.31M |
| Shares Outstanding | 158.31M |
| Shares Change (YoY) | +0.15% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 3.08% |
| Owned by Institutions (%) | 1.42% |
| Float | 32.29M |
Valuation Ratios
The trailing PE ratio is 45.38 and the forward PE ratio is 35.49. NSE:ARTEMISMED's PEG ratio is 1.25.
| PE Ratio | 45.38 |
| Forward PE | 35.49 |
| PS Ratio | 4.64 |
| PB Ratio | 5.49 |
| P/TBV Ratio | 5.86 |
| P/FCF Ratio | 191.19 |
| P/OCF Ratio | 39.12 |
| PEG Ratio | 1.25 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.69, with an EV/FCF ratio of 199.87.
| EV / Earnings | 47.48 |
| EV / Sales | 4.85 |
| EV / EBITDA | 26.69 |
| EV / EBIT | 34.68 |
| EV / FCF | 199.87 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.29 |
| Debt / FCF | 9.69 |
| Interest Coverage | 6.61 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 9.98% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 6.06% |
| Revenue Per Employee | 5.42M |
| Profits Per Employee | 553,046 |
| Employee Count | 2,055 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:ARTEMISMED has paid 380.63 million in taxes.
| Income Tax | 380.63M |
| Effective Tax Rate | 25.04% |
Stock Price Statistics
The stock price has increased by +36.17% in the last 52 weeks. The beta is 0.32, so NSE:ARTEMISMED's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +36.17% |
| 50-Day Moving Average | 284.22 |
| 200-Day Moving Average | 260.31 |
| Relative Strength Index (RSI) | 70.38 |
| Average Volume (20 Days) | 557,634 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:ARTEMISMED had revenue of INR 11.14 billion and earned 1.14 billion in profits. Earnings per share was 7.19.
| Revenue | 11.14B |
| Gross Profit | 2.55B |
| Operating Income | 1.56B |
| Pretax Income | 1.52B |
| Net Income | 1.14B |
| EBITDA | 1.97B |
| EBIT | 1.56B |
| Earnings Per Share (EPS) | 7.19 |
Balance Sheet
The company has 334.05 million in cash and 2.62 billion in debt, with a net cash position of -2.28 billion or -14.41 per share.
| Cash & Cash Equivalents | 334.05M |
| Total Debt | 2.62B |
| Net Cash | -2.28B |
| Net Cash Per Share | -14.41 |
| Equity (Book Value) | 9.41B |
| Book Value Per Share | 59.04 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 1.32 billion and capital expenditures -1.05 billion, giving a free cash flow of 270.01 million.
| Operating Cash Flow | 1.32B |
| Capital Expenditures | -1.05B |
| Depreciation & Amortization | 417.41M |
| Net Borrowing | -166.08M |
| Free Cash Flow | 270.01M |
| FCF Per Share | 1.71 |
Margins
Gross margin is 22.91%, with operating and profit margins of 13.97% and 10.21%.
| Gross Margin | 22.91% |
| Operating Margin | 13.97% |
| Pretax Margin | 13.65% |
| Profit Margin | 10.21% |
| EBITDA Margin | 17.72% |
| EBIT Margin | 13.97% |
| FCF Margin | 2.50% |
Dividends & Yields
This stock pays an annual dividend of 0.45, which amounts to a dividend yield of 0.14%.
| Dividend Per Share | 0.45 |
| Dividend Yield | 0.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.15% |
| Shareholder Yield | -0.01% |
| Earnings Yield | 2.20% |
| FCF Yield | 0.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:ARTEMISMED is 345.60, which is 5.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 345.60 |
| Price Target Difference | 5.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 26.91% |
| EPS Growth Forecast (3Y) | 34.74% |
Stock Splits
The last stock split was on September 23, 2021. It was a forward split with a ratio of 10.
| Last Split Date | Sep 23, 2021 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |